Kicking off this discussion thread for ongoing community input on cognitive and nootropic peptide research questions. This is the smallest active category on the platform but the compounds in it are interesting enough that there should be more discussion than there currently is. Rather than wait for an active community to materialize, I want to seed this thread with specific questions and experience-types that lurkers can use as onramps. Reply with your own questions or respond to anyone else's.
Specific questions or experiences worth sharing.
Semax intranasal protocol experiences. If a research protocol used intranasal Semax, what concentration was the formulation, how many drops or sprays per dose, what frequency through the day, and over what timeframe? What endpoints were tracked — focus, mood, cognitive performance on standardized tests, subjective wellbeing? What did the time course of observed effects look like — immediate after dose, accumulating over days, or persistent for weeks after discontinuation? The intranasal pharmacokinetics of Semax produce different effect patterns than conventional pharmacological agents and community-level experience reports add to a thinner literature base.
Selank for stress and anxiety research. Selank has been studied for anxiolytic effects without the dependence and withdrawal profile of conventional anxiolytics. If a research protocol used Selank for stress or anxiety endpoints, what dosing pattern was used, over what timeframe, and how did the observed effects compare to other anxiolytic interventions in your research history? Did the effects persist after discontinuation or fade with cessation?
Semax versus Selank head-to-head experiences. If a protocol compared Semax and Selank (sequentially or in different research arms), what differences were observed in subjective effects, in response timeframe, or in the effect-after-discontinuation pattern? The two compounds are often discussed together because they share the intranasal Russian-research origin but they have different mechanisms and different research applications.
Cerebrolysin experiences and source verification. Cerebrolysin has the largest clinical research base of the compounds in this category but the source-verification problem is real for community use. If a research protocol used Cerebrolysin, what was the source, what dosing protocol was followed, and how was authenticity verified? Pharmaceutical-grade through verifiable channels versus research-grade through peptide vendors produces fundamentally different research conditions.
Combination protocols. If a research protocol combined cognitive peptides with each other (Semax + Selank as a common combination) or with non-peptide nootropics, what was the rationale and what was observed? The combination research base is essentially absent from published literature so community-level experience reports add to a literally empty data set.
A note on framing.
This category attracts researchers interested in cognitive endpoints, mood and stress endpoints, and recovery from neurological insults. Please specify the research context when describing protocols. Cognitive enhancement research in healthy subjects has a different design space than stroke recovery research or anxiety modulation research, and the appropriate dosing patterns and endpoint tracking differ substantially.
A specific note on Dihexa: the published research base is thinner than the marketing community typically conveys. Experience reports with Dihexa are welcome but please be specific about what you observed and what protocols were used, and avoid overclaiming based on the strong marketing language some vendors use for this compound. The Red Flags thread in this category covers the marketing problem in more detail.
If you have questions but do not want to post them publicly, DMs are open. The thread is the right place for shareable Q&A but private messages work for protocol-specific or vendor-specific questions, particularly for Cerebrolysin sourcing.
